Jump to Main Content
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
- Odunsi, Kunle, Matsuzaki, Junko, Karbach, Julia, Neumann, Antje, Mhawech-Fauceglia, Paulette, Miller, Austin, Beck, Amy, Morrison, Carl D., Ritter, Gerd, Godoy, Heidi, Lele, Shashikant, duPont, Nefertiti, Edwards, Robert, Shrikant, Protul, Old, Lloyd J., Gnjatic, Sacha, Jäger, Elke
- Proceedings of the National Academy of Sciences of the United States of America 2012 v.109 no.15 pp. 5797-5802
- CD8-positive T-lymphocytes, Poxviridae, animal ovaries, antigens, clinical trials, fowl pox, immune response, melanoma, ovarian neoplasms, patients, risk, secondary immunization, vaccination, vaccines
- Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical trials as cancer vaccines to induce tumor-specific immune responses that will improve clinical outcome. To test whether a diversified prime and boost regimen targeting NY-ESO-1 will result in clinical benefit, we conducted two parallel phase II clinical trials of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1), followed by booster vaccinations with recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in 25 melanoma and 22 epithelial ovarian cancer (EOC) patients with advanced disease who were at high risk for recurrence/progression. Integrated NY-ESO-1-specific antibody and CD4+ and CD8+ T cells were induced in a high proportion of melanoma and EOC patients. In melanoma patients, objective response rate [complete and partial response (CR+PR)] was 14%, mixed response was 5%, and disease stabilization was 52%, amounting to a clinical benefit rate (CBR) of 72% in melanoma patients. The median PFS in the melanoma patients was 9 mo (range, 0–84 mo) and the median OS was 48 mo (range, 3–106 mo). In EOC patients, the median PFS was 21 mo (95% CI, 16–29 mo), and median OS was 48 mo (CI, not estimable). CD8+ T cells derived from vaccinated patients were shown to lyse NY-ESO-1-expressing tumor targets. These data provide preliminary evidence of clinically meaningful benefit for diversified prime and boost recombinant pox-viral-based vaccines in melanoma and ovarian cancer and support further evaluation of this approach in these patient populations.